glp 1 drug made by eli lilly FDA approves new weight-loss pill, Foundayo Orforglipron: Eli Lilly's New Oral

Abstract Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists have emerged as treatment options for type 2 diabetes mellitus (T2DM)

GLP-1RA can help maintain a balance of energy metabolism in cardiomyocytes through activating PI3K/Akt as well as p38 MAPK pathways as well as activating Nrf-2/heme oxygenase-1 (HO-1), contributing to augmented adenosine triphosphate formation and glucose ingestion by cardiomyocytes [153-155]

NaB-enhanced hepatic GLP-1R expression via inhibiting HDAC It has been reported that short-chain fatty acids (SCFAs) including NaB are able to regulate the immune response and metabolism through the activation of GPRs, such as GRP43 and GRP109a or through the inhibition of HDAC 27,28

In addition, in recent years, a significant role has been attributed to coronary microvascular dysfunction as one of the pathogenetic factors for HFpEF progression

Nature in November 2023

Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice